Last reviewed 2026-04-22 · How we verify

Conventional glucocortidois

Conventional glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.

Conventional glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis), Allergic and asthmatic conditions, Adrenal insufficiency.

At a glance

Mechanism of action

Glucocorticoids enter cells and bind to intracellular glucocorticoid receptors, which translocate to the nucleus and regulate transcription of pro-inflammatory and anti-inflammatory genes. This leads to decreased production of cytokines, chemokines, and adhesion molecules, reducing immune cell activation and migration. The result is broad immunosuppression and anti-inflammatory effects across multiple tissues.

Approved indications

• Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)
• Allergic and asthmatic conditions
• Adrenal insufficiency
• Certain hematologic malignancies and lymphomas

Common side effects

• Hyperglycemia
• Hypertension
• Osteoporosis
• Infections (opportunistic)
• Cushingoid features
• Mood disturbances
• Gastrointestinal upset

Key clinical trials

• Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Conventional glucocortidois CI brief — competitive landscape report
• Conventional glucocortidois updates RSS · CI watch RSS
• University of Palermo portfolio CI